• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ACADIA Pharmaceuticals (ACAD) Wins EU Approval For DAYBU, Is The 16% Upside Still There?

    Simply Wall St·09/05/2026 22:22:58
    Listen to the news

    EC approval for DAYBU reshapes ACADIA Pharmaceuticals stock story

    ACADIA Pharmaceuticals (ACAD) is back in focus after the European Commission granted marketing authorization for DAYBU, the first approved treatment for Rett syndrome in the European Union.

    The decision opens access across all 27 EU member states, plus Iceland, Liechtenstein and Norway, and is based on Phase 3 LAVENDER results showing clinically meaningful improvements in core Rett syndrome symptoms.

    ACADIA Pharmaceuticals’ share price has gained 30.0% over the past 90 days and the 1-year total shareholder return is 10.9%. This suggests that investors have been warming to the growth story, even though the 7-day share price return is down 3.7% following recent news.

    Extend your research beyond ACADIA Pharmaceuticals by scanning a curated set of rare disease and complex care peers in our list of solid balance sheet and fundamentals (52 results) for potential ideas focused on quality and resilience.

    The sharp 90 day gain in ACADIA Pharmaceuticals, alongside softer recent trading, leaves an open question: Is the price now tracking a stronger DAYBU driven business, or has sentiment simply swung ahead of what the numbers support?

    Most Popular Narrative: 15.7% Undervalued

    Compared with ACADIA Pharmaceuticals’ last close at $28.02, the most followed narrative sees fair value at $33.25, implying a material valuation gap if those assumptions hold.

    ACADIA's pipeline momentum, with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027, positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.

    Read the complete narrative. Read the complete narrative.

    Curious what justifies that higher fair value for ACADIA Pharmaceuticals? The narrative leans heavily on projected revenue expansion, changing margin structure, and a richer earnings multiple. The exact assumptions may surprise you.

    The fair value framework behind $33.25 weaves together expected revenue growth, a step down in profit margins from current levels, and a higher future P/E multiple than the broader US Biotechs sector. It also factors in how many shares analysts think ACADIA Pharmaceuticals may issue over time and discounts those future earnings back using a 7.25% rate, which affects how much weight is placed on cash flows several years out.

    Result: Fair Value of $33.25 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, ACADIA Pharmaceuticals still faces meaningful risks if remlifanserin data disappoint or if higher R&D and SG&A spending weighs more heavily on profitability than analysts expect.

    Find out about the key risks to this ACADIA Pharmaceuticals narrative.

    Next Steps

    Mixed signals around ACADIA Pharmaceuticals can be confusing. Check the underlying data now and shape your own view by weighing the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond ACADIA Pharmaceuticals?

    If you stop with ACADIA Pharmaceuticals, you risk missing other compelling set ups. Use the Simply Wall St Screener to uncover fresh opportunities that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.